Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?

Executive Summary

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.

Advertisement

Related Content

Laboratory For Advanced Medicine (LAM) Appoints Chief Regulatory Officer
ANGLE Reels In First Patient For Major US FDA Clinical Study
Oncimmune Reels In New Strategy Head And More Capital
Abbott Strikes Deal With British Liquid Biopsy Company Angle
Oncimmune Kicks Off 2018 With China Pact For Lung Cancer Test
Start-Up Spotlight: Indi, Liquid Biopsy To Rule Out Lung Cancer
Inivata Names New Chief Operations Officer
VC Deals Analysis: Liquid Biopsy Summons Yet Another Top A-Lister
Sophia Genetics' AI Brings In More Standardization To Liquid Biopsies
New Chronix Liquid Biopsy Test Could Save Doctors On Immunotherapy Costs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT122637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel